Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity

被引:14
作者
Bizzarri, Bruno Mattia [1 ]
Tortolini, Silvia [1 ]
Rotelli, Luca [1 ]
Botta, Giorgia [1 ]
Saladino, Raffaele [1 ]
机构
[1] Univ Tuscia, Dipartimento Ecol & Biol, Via S Camillo de Lellis Snc, I-01100 Viterbo, Italy
关键词
L-DOPA; Parkinson; peptidomimetics; biological and pharmacological activity; synthesis; EARLY PARKINSONS-DISEASE; L-TYROSINE; AMINO-ACID; INDUCED DYSKINESIA; OXIDATIVE STRESS; CEREBROSPINAL-FLUID; SUBSTANTIA-NIGRA; BASAL GANGLIA; BETA-PEPTIDES; IN-VITRO;
D O I
10.2174/0929867322666150625095748
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
L-3,4-Dihydroxyphenylalanine [2-amino-3-(3,4-dihydroxyphenyl) propanoic acid (L-DOPA) is a natural constituent of animal and plant tissue derived from post-translational modification of the amino acid tyrosine. L-DOPA is modified during metabolism to catecholamine neurotransmitters, noradrenaline and adrenaline, which are characterized by different biological activities. L-DOPA has been the first drug of choice in the therapy of Parkinson's disease that is a progressive neurodegenerative disorder involving the loss of dopaminergic neurons of substantia nigra pars compacta. The social and economic impact of these diseases is very high due to the progressive aging of the population. This review focuses on the biological effect of L-DOPA, as well as on the synthesis of L-DOPA derivatives and their application in central nervous system diseases. Among them, L-DOPA-containing peptides (L-DOPA-Pep) show important biological and pharmacological activities. For example, L-DOPA analogues of the alpha-factor interact with models of the G protein-coupled receptor, inhibit the oxidation of low-density lipoproteins, and are used for improving L-DOPA absorption in long-term treatment of Parkinson's disease and as skin moisturizer in cosmetic compositions. Moreover, L-DOPA residues in proteins provide reactive tools for the preparation of adhesives and coatings materials. Usually, L-DOPA-Pep is prepared by traditional liquid or solid state procedures starting from simple amino acids. Recently, selective side-chain modifications of pre-formed peptides have also been reported both for linear and branched peptides. Here, we describe the recent advances in the synthesis of L-DOPA and dopa-peptidomimetics and their biological and pharmacological activities, focusing the attention on new synthetic procedures and biological mechanism of actions.
引用
收藏
页码:4138 / 4165
页数:28
相关论文
共 50 条
  • [21] Role of L-DOPA in Spinal Nociceptive Reflex Activity: Higher Sensitivity of Aδ Versus C Fibre-Evoked Nociceptive Reflexes to L-DOPA
    Schomburg, E. D.
    Dibaj, P.
    Steffens, H.
    PHYSIOLOGICAL RESEARCH, 2011, 60 (04) : 701 - 703
  • [22] Herbs containing L-Dopa: An update
    Kuber, Ramya B.
    Thaakur, SanthRani
    ANCIENT SCIENCE OF LIFE, 2007, 27 (01) : 50 - 55
  • [23] L-Dopa activates histaminergic neurons
    Yanovsky, Yevgenij
    Li, Sha
    Klyuch, Boris P.
    Yao, Qiaoling
    Blandina, Patrizio
    Passani, M. Beatrice
    Lin, Jian-Sheng
    Haas, Helmut L.
    Sergeeva, Olga A.
    JOURNAL OF PHYSIOLOGY-LONDON, 2011, 589 (06): : 1349 - 1366
  • [24] Spectroelectrochemical and voltammetric studies of L-DOPA
    Liu, XQ
    Zhang, ZL
    Cheng, GJ
    Dong, SJ
    ELECTROANALYSIS, 2003, 15 (02) : 103 - 107
  • [25] Overview on the biotechnological production of L-DOPA
    Min, Kyoungseon
    Park, Kyungmoon
    Park, Don-Hee
    Yoo, Young Je
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2015, 99 (02) : 575 - 584
  • [26] TOWARDS DEFINING RECEPTORS FOR L-TYROSINE AND L-DOPA
    SLOMINSKI, A
    PAUS, R
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1994, 99 (02) : C7 - C11
  • [27] Dual effects of L-DOPA on nigral dopaminergic neurons
    Guatteo, Ezia
    Yee, Andrew
    McKearney, James
    Cucchiaroni, Maria L.
    Armogida, Marta
    Berretta, Nicola
    Mercuri, Nicola B.
    Lipski, Janusz
    EXPERIMENTAL NEUROLOGY, 2013, 247 : 582 - 594
  • [28] L-dopa induced dyskinesia in Parkinson's disease
    Bastide, Matthieu F.
    Bezard, Erwan
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2015, 199 (2-3): : 201 - 212
  • [29] Peculiarities of L-DOPA treatment of Parkinson's disease
    Kostrzewa, RM
    Nowak, P
    Kostrzewa, JP
    Kostrzewa, RA
    Brus, R
    AMINO ACIDS, 2005, 28 (02) : 157 - 164
  • [30] What can we expect from the serotonergic side of L-DOPA?
    De Deurwaerdere, P.
    Nauailles, S.
    REVUE NEUROLOGIQUE, 2012, 168 (12) : 927 - 938